<DOC>
	<DOCNO>NCT00422812</DOCNO>
	<brief_summary>Staccato Prochlorperazine develop treat patient suffer acute migraine headache . In October 2005 , complete 75 patient , multi-center , double-blind placebo-controlled Phase 2A clinical trial patient suffer moderate severe acute migraine headache . This Phase 2B clinical trial Staccato Prochlorperazine initiate assess efficacy safety outpatient migraine headache without aura .</brief_summary>
	<brief_title>StaccatoÂ® Prochlorperazine Inhalation Migraine</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<criteria>1 . Male female patient age 18 70 year , inclusive . 2 . Patients migraine headache without aura ( diagnosis accord International Headache Society guideline ) least 6 month . 3 . Patients history migraine least 3 migraine attack last 3 month period ( 8 migraine attack per month ) . Current past migraine medication history must record . 4 . Patients agree : use study drug within 72 hr prior migraine attack , use investigational medication pain rating Moderate Severe ( None , Mild , Moderate Severe Scale ) prior dose . 5 . Patients speak , read , understand English sufficiently well willing able provide write informed consent IRB approve form prior initiation study procedure . 6 . Patients willing able comply study schedule study requirement , agree return clinic within 5 work day use investigational treatment . 7 . Patients good general health prior study participation determine detailed medical history , physical examination , 12lead ECG , blood chemistry profile , hematology , urinalysis opinion Principal Investigator . 8 . Female participant ( childbearing potential sexually active ) male participant ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method throughout study one week follow end study . Medically acceptable method contraception may use participant and/or his/her partner include abstinence , birth control pills patch , diaphragm spermicide , intrauterine device ( IUD ) , condom foam spermicide , vaginal spermicidal suppository , surgical sterilization progestin implant injection . Prohibited method include : rhythm method , withdrawal , condoms alone , diaphragm alone . 1 . Patients currently take tricyclic antidepressant , valproate , divalproex , barbital , thiazolidinediones , phenothiazine , benzodiazepine , lithium hepatic toxic drug must exclude . 2 . Patients currently take medication prolong QT/QTc interval ( see Appendix 4 ) must exclude . 3 . Patients history contraindication anticholinergic ( bowel obstruction , urinary retention , acute glaucoma ) must exclude . 4 . Patients history allergy intolerance phenothiazine relate drug ( prochlorperazine , chlorpromazine , promethazine , mesoridazine , thioridazine , fluphenazine , perphenazine ) must exclude . 5 . Patients history extrapyramidal disorder , movement disorder , neuroleptic malignant syndrome , major affective disorder must exclude . 6 . Female patient positive pregnancy test screen breastfeeding must exclude . 7 . Patients history within past year drug alcohol dependence abuse define DSM4 must exclude . 8 . Patients history pheochromocytoma , seizure disorder Parkinson 's disease must exclude . 9 . Patients history syncope , unstable angina , myocardial infarction ( within 6 mo ) , congestive heart failure , transient ischemic attack must exclude . 10 . Patients history major neurological disorder migraine ( subarachnoidal bleeding , stroke , brain tumor ) must exclude . 11 . Patients disease ( ) , history , physical examination , laboratory abnormality ( ALT AST &gt; 2fold upper limit normal , Bilirubin &gt; 1.5 mg/dL , creatinine &gt; 1.8 mg/dL ) investigator 's opinion , would present undue risk patient may confound interpretation study result must exclude . 12 . Patients history asthma chronic obstructive lung disease exclude . 13 . Patients receive investigational drug within 30 day prior Screening Visit must exclude . 14 . Patients history risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) must exclude . 15 . Patients marked prolongation QT/QTc interval ( e.g. , demonstration QT interval &gt; 450 m screen ECG ) must exclude . 16 . Patients consider investigator , reason , unsuitable candidate receiving prochlorperazine , unable use inhalation device , must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Migraine , Staccato Prochlorperazine</keyword>
	<keyword>Migraine headache without aura .</keyword>
</DOC>